Matsukiyococokara & Co. · TSE:3088
Matsukiyococokara & — Q3 FY2024 Earnings Presentation
15 slides from Matsukiyococokara &'s earnings presentation, Feb 14, 2025
Slide 1: Financial Results for the Nine Months Ended December 31, 2024
This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail. Financial Results for the Nine Months Ended December 31, 2024 Copyright 2025 February 14, 2025 Ma
Slide 2: Table of Contents
Table of Contents Financial Results for 3Q FY2024 Financial Summary (Nine Months) ・・・・・・ 3 Segment Results (Nine Months) ・・・・・・ 4 Segment Results (Nine Months) (Reference) Excluding amortization of goodwill and trademark rights associated with the management ・・・・・・ 5 integration with cocokarafine In
Slide 3: Financial Summary (Nine Months)
Financial Results for 3Q FY2024 Financial Summary (Nine Months) ◼ Sales increased due to strong sales, especially in cosmetics and medical & pharmaceutical products, as a result of the recovery in human flow and duty-free sales. ◼ Despite upfront investments in human capital and systems, profit incr
Slide 4: Segment Results (Nine Months)
Financial Results for 3Q FY2024 Segment Results (Nine Months) ◼ Matsumotokiyoshi Group recorded an increase in sales and profit against the backdrop of increased flow of people in urban areas and downtown and an increase in overseas tourists visiting Japan. ◼ Cocokarafine Group secured an increase i
Slide 5: Segment Results (Nine Months) (Reference)
Financial Results for 3Q FY2024 Segment Results (Nine Months) Excluding amortization of goodwill and trademark rights totaling 5,427 million yen associated Reference with the management integration with cocokara fine Inc. (Millions of yen) Nine Months Ended Nine Months Ended December 31, 2023 Decemb
Slide 6: Segment Results (3Q)
Financial Results for 3Q FY2024 Segment Results (3Q) ◼ Against the backdrop of expanding human flow in urban and downtown areas, an increase overseas tourists visiting Japan, and strong sales of winter seasonal products, both Matsumotokiyoshi Group and Cocokarafine Group businesses posted double-dig
Slide 7: Segment Results (3Q) (Reference)
Financial Results for 3Q FY2024 Segment Results (3Q) Excluding amortization of goodwill and trademark rights totaling 1,809 million yen associated Reference with the management integration with cocokara fine Inc. (Millions of yen) 3Q FY2023 3Q FY2024 (Oct - Dec 2023) (Oct - Dec 2024) Change Change (
Slide 8: Net Sales by Product
Financial Results for 3Q FY2024 Net Sales by Product ◼ Increase in our focused health and beauty categories ◼ Gross profit margin improved due to steady implementation of priority measures and expanded sales of high value-added products. (Millions of yen) Net sales Gross profit margin(％) April - Dec
Slide 9: Balance Sheet
Financial Results for 3Q FY2024 Balance Sheet ◼ Equity ratio 70.7％ (Millions of yen) End of December, End of March, 2024 Change 2024 Current assets 370,798 368,072 (2,726) Cash and deposits 117,720 108,920 (8,800) Accounts receivable - trade 61,747 69,262 7,515 Merchandise 138,573 145,857 7,283 Non-
Slide 10: Store Openings, Closings, and Renovations in Japan
Financial Results for 3Q FY2024 Store Openings, Closings, and Renovations in Japan ◼ 3Q Cumulative Period (Unit: No. of stores) Number of stores Openings Closings Renovations Number of stores as of March 31, 2024 in 9 months in 9 months in 9 months as of Dec 31, 2024 Matsumotokiyoshi Group 1,904 42
Slide 11: FY2024 Financial Forecasts
Financial Forecasts for FY2024 FY2024 Financial Forecasts ◼ There are no revisions to the consolidated earnings forecast announced on May 10, 2024 (Millions of yen) Full Year FY2023 FY2024 Change Change % to net sales % to net sales (amount) (%) Net sales 1,022,531 1,050,000 27,468 2.7 Gross profit
Slide 12: Quarterly Consolidated Financial Results
【Appendix】 Quarterly Consolidated Financial Results FY2023 FY2024 （Millions of yen/%） 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Net sales 248,222 259,544 262,566 252,197 1,022,531 259,749 265,979 275,791 Gross profit 84,199 89,627 91,074 89,197 354,097 89,241 93,115 96,201 Gross profit margin 33.9
Slide 13: Quarterly Segment Results
【Appendix】 Quarterly Segment Results FY2023 FY2024 （Millions of yen/％） 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Sales 152,810 159,867 162,999 157,439 633,117 162,010 166,075 173,795 Matsumoto- kiyoshi Segment profit 11,783 12,937 14,267 12,753 51,741 12,560 13,647 16,242 Group Business Segment pr
Slide 14: Quarterly Net Sales and Gross Profit by Product
【Appendix】 Quarterly Net Sales and Gross Profit by Product FY2023 FY2024 (Millions of yen/％) 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Medical and Sales 85,192 91,340 93,264 92,095 361,892 88,378 90,809 96,478 pharmaceuti Segment profit 35,218 40,039 40,416 40,961 156,636 37,069 40,665 42,564 cal
Slide 15: Cautionary Statement
Cautionary Statement This document contains future outlooks such as plans, forecasts, strategies, and others which are not historical fact and these are made by the management’s judgement based on the obtainable information at the time of the disclosure. Actual results may significantly differ from
MatsukiyoCocokara & — Q3 FY2024 Earnings Presentation on 6ix